Researchers reported that cGAS–STING hyperactivation drives liver inflammation in Down syndrome, providing a mechanistic explanation for hepatic vulnerability in the condition. The study highlights how innate immune sensing pathways, when overactive due to trisomy biology, can amplify inflammatory signaling in the liver. The work connects broader Down syndrome immunopathology to a specific intracellular pathway that is targetable in principle through inhibitors of cGAS–STING signaling. While the report is preclinical-mechanistic in this summary, it sets up a clear hypothesis for therapeutic testing. For biotech, the development adds to the expanding list of DS-associated biology that can translate into pathway-directed drug discovery programs.